• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    4/22/21 9:10:09 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CBPO alert in real time by email
    SC 13D/A 1 tm2113748d1_sc13da.htm SCHEDULE 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 17)*

     

    China Biologic Products Holdings, Inc.

    (Name of Issuer)

     

    Ordinary Shares, Par Value $0.0001

    (Title of Class of Securities)

     

    G21515104

    (CUSIP Number)

     

    Andrew Chan

    Chief Financial Officer

    Centurium Capital Management Ltd.

    Suite 1008, Two Pacific Place, 88 Queensway, Hong Kong

    +852 3643 0755

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and
    Communications)

     

    April 20, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 1(f) or 1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Beachhead Holdings Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Double Double Holdings Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0.0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Point Forward Holdings Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Centurium Capital Partners 2018, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Centurium Capital Partners 2018 GP Ltd.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

      

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Centurium Capital 2018 Co-invest, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    CCM CB I, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Centurium Capital 2018 SLP-B Ltd.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    10 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    CCM CB I Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5) (1)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Centurium Holdings Ltd.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Centurium Holdings (BVI) Ltd.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    British Virgin Islands

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. G21515104  
    1.

    Names of Reporting Persons.

     

    Hui Li

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions).

     

    (a) x (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    N/A

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Hong Kong

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    7.

    Sole Voting Power

     

    0 (See Item 5)

    8.

    Shared Voting Power

     

    0 (See Item 5)

    9.

    Sole Dispositive Power

     

    0 (See Item 5)

    10.

    Shared Dispositive Power

     

    0 (See Item 5)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 (See Item 5)

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%

    14.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    Pursuant to Rule 13d-2 promulgated under the Act, this amendment to Schedule 13D (this “Amendment No. 17”) amends and supplements the Schedule 13D filed on September 14, 2018, as amended by Amendment No. 1 filed on November 19, 2018, by Amendment No. 2 filed on December 18, 2018, by Amendment No. 3 filed on January 8, 2019, by Amendment No. 4 filed on February 4, 2019, by Amendment No. 5 filed on March 12, 2019, by Amendment No. 6 filed on September 19, 2019, by Amendment No. 7 filed on November 18, 2019, by Amendment No. 8 filed on January 24, 2020, by Amendment No. 9 filed on March 20, 2020, by Amendment No. 10 filed on April 10, 2020, by Amendment No. 11 filed on May 1, 2020, by Amendment No. 12 filed on May 7, 2020, by Amendment No. 13 filed on September 17, 2020, by Amendment No. 14 filed on October 28, 2020, by Amendment No. 15 filed on November 20, 2020 and by Amendment No. 16 filed on December 31, 2020 (the “Schedule 13D”), with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of China Biologic Products Holdings, Inc., a company organized under the laws of the Cayman Islands (the “Issuer”).

     

    Except as specifically provided herein, this Amendment No. 17 does not modify any of the information previously reported in the Schedule 13D. All capitalized terms used and not defined herein have the meanings given to such terms in the Schedule 13D.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

     

    On April 20, 2021, the Issuer and Merger Sub filed the plan of merger with the Registrar of Companies of the Cayman Islands, which was registered by the Registrar of Companies of the Cayman Islands as of April 20, 2021, pursuant to which the Merger became effective on April 20, 2021. As a result of the Merger, the Issuer became a wholly owned subsidiary of Parent.

     

    At the Effective Time of the Merger, each Ordinary Share issued and outstanding immediately prior to the effective time of the Merger was cancelled and ceased to exist in exchange for the right to receive US$120.00 per share in cash, without interest and net of any applicable withholding taxes, except for (a) Ordinary Shares held by the Issuer as treasury shares or by any direct or indirect subsidiary of the Issuer, which were cancelled and ceased to exist without consideration, (b) Ordinary Shares held by Parent or any direct or indirect subsidiary of Parent (including Ordinary Shares deemed contributed by the Rollover Securityholders to Parent immediately prior to or at the Effective Time of the Merger pursuant to the Support Agreement), which were cancelled and ceased to exist without consideration, (c) Ordinary Shares owned by holders who have validly exercised and not effectively withdrawn or lost their rights to dissent from the merger pursuant to Section 238 of the Companies Law of the Cayman Islands, which were cancelled and ceased to exist in exchange for the right to receive the payment of fair value of such Ordinary Shares determined in accordance with Section 238 of the Companies Law of the Cayman Islands, and (d) Ordinary Shares owned by holders who had previously validly exercised their rights to dissent from the Merger pursuant to Section 238 of the Companies Law of the Cayman Islands and thereafter have effectively withdrawn such rights to dissent pursuant to agreements entered into between such holders and the Issuer prior to the effective time of the Merger, which were cancelled and ceased to exist in exchange for the right to receive such amounts as specified in such agreements.

     

    As a result of the Merger, the Ordinary Shares ceased to trade on the NASDAQ Global Select Market prior to the opening of trading on April 21, 2021 and became eligible for delisting from the NASDAQ Global Select Market and termination of registration pursuant to Rules 12g-4(a)(1) and 12h-3(b)(1)(i) of the Exchange Act.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

     

    (a)–(b) As a result of the Merger, as described in Item 4 of this Amendment, the Reporting Persons do not beneficially own any Ordinary Shares or have any voting power or dispositive power over any Ordinary Shares.

     

    (c) Except as set forth in Item 4 of this Amendment No. 17 or previously reported in the Schedule 13D, to the knowledge of each of the Reporting Persons, none of the Reporting Persons has effected any transactions in the Ordinary Shares during the past 60 days.

     

    (d) Not applicable.

     

    (e) April 20, 2021.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date: April 22, 2021
       
      BEACHHEAD HOLDINGS LIMITED
       
       
      By:  /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      DOUBLE DOUBLE HOLDINGS LIMITED
       
       
      By:  /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      POINT FORWARD HOLDINGS LIMITED
       
       
      By:  /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CENTURIUM CAPITAL PARTNERS 2018, L.P.
       
       
      By: CENTURIUM CAPITAL PARTNERS 2018 GP LTD., GENERAL PARTNER
         
         
      By:  /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CENTURIUM CAPITAL PARTNERS 2018, GP LTD.
       
       
      By:  /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CENTURIUM CAPITAL 2018 CO-INVEST, L.P.
       
       
      By: CENTURIUM CAPITAL 2018 SLP-B LTD., GENERAL PARTNER
         
         
      By: /s/ Hui Li
        Name: HUI LI
        Title: Director

     

     

     

     

     

    CENTURIUM CAPITAL 2018 SLP-B LTD.

       
       
      By: /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CCM CB I, L.P.
       
       
      By: CCM CB I Limited, GENERAL PARTNER
         
         
      By: /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CCM CB I Limited
       
       
      By: /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CENTURIUM HOLDINGS LTD.
       
       
      By: /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      CENTURIUM HOLDINGS (BVI) LTD.
       
       
      By: /s/ Hui Li
        Name: HUI LI
        Title: Director

     

      HUI LI
       
       
      By: /s/ Hui Li

     

     

    Get the next $CBPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CBPO
    SEC Filings

    View All

    SEC Form 15-12B filed by China Biologic Products Holdings, Inc.

    15-12B - China Biologic Products Holdings, Inc. (0001369868) (Filer)

    4/30/21 6:13:29 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by China Biologic Products Holdings, Inc.

    S-8 POS - China Biologic Products Holdings, Inc. (0001369868) (Filer)

    4/21/21 8:52:06 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by China Biologic Products Holdings, Inc.

    S-8 POS - China Biologic Products Holdings, Inc. (0001369868) (Filer)

    4/21/21 8:50:57 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    China Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ "Deal of the Year - Large Cap"

    HONG KONG, Nov. 16, 2021 /PRNewswire/ -- The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. ("China Biologic" or the "Company") was awarded "Deal of the Year – Large Cap" by Asia Venture Capital Journal (AVCJ) at its annual award ceremony on November 15 in Hong Kong. A buyer consortium led by Centurium Capital first announced its indicative proposal to privatize the Nasdaq-listed China Biologic (NASDAQ:CBPO) on September 18, 2019. On November 19, 2020, the two sides had reached an agreement for the consortium to purchase the outstanding shares not already owned by the consortium members at US$120 per share, implying

    11/16/21 10:11:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    China Biologic Announces Completion of Going Private Transaction

    BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ:CBPO, ", China Biologic", or the ", Company", ))), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger Sub"), a wholly owned subsidiary of CBPO Holdings Limited ("Parent"), pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement") among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company. Pursuant to the terms of the

    4/20/21 4:30:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

    BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019. Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019. Income from operations increased

    3/29/21 4:30:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

    4/22/21 4:23:32 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

    4/22/21 9:15:17 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

    4/22/21 9:10:09 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBPO
    Financials

    Live finance-specific insights

    View All

    China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

    BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019. Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019. Income from operations increased

    3/29/21 4:30:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care